We serve Chemical Name:3,6-diiodopyridine-2-carbonitrile CAS:827616-53-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,6-diiodopyridine-2-carbonitrile
CAS.NO:827616-53-5
Synonyms:2-CYANO-3,6-DIIODOPYRIDINE;2-Pyridinecarbonitrile,3,6-diiodo;MFCD09037452
Molecular Formula:C6H2I2N2
Molecular Weight:355.90200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:388.8ºC at 760 mmHg
Density:2.68g/cm3
Index of Refraction:1.769
PSA:36.68000
Exact Mass:355.83100
LogP:2.16248
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3439 6.1/PG 3
Packing Group:III
Contact us for information like 2-CYANO-3,6-DIIODOPYRIDINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD09037452 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-CYANO-3,6-DIIODOPYRIDINE Use and application,2-Pyridinecarbonitrile,3,6-diiodo technical grade,usp/ep/jp grade.
Related News: One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 3,6-diiodopyridine-2-carbonitrile manufacturer ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. 3,6-diiodopyridine-2-carbonitrile supplier Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. 3,6-diiodopyridine-2-carbonitrile vendor In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers. 3,6-diiodopyridine-2-carbonitrile factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.
